Drug
SHR-1139 Injection
SHR-1139 Injection is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
3
75%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Active, not recruiting2
Not yet recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
active_not_recruiting250%
not_yet_recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
active_not_recruitingphase_1
A Trial of SHR-1139 in Healthy Volunteers
NCT07078695
not_yet_recruitingphase_2
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
NCT07444684
not_yet_recruitingphase_2
A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
NCT07337564
active_not_recruitingphase_2
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
NCT06875934
Clinical Trials (4)
Showing 4 of 4 trials
NCT07078695Phase 1
A Trial of SHR-1139 in Healthy Volunteers
NCT07444684Phase 2
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
NCT07337564Phase 2
A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
NCT06875934Phase 2
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4